Manganese porphyrin given at symptom onset markedly extends survival of ALS mice

Annals of Neurology

Volumn 58, Issue 2, 2005, Pages 258-265

  Crow, John P ^a   Calingasan, Noel Y ^b   Chen, Junyu ^b   Hill, Julie Lynch ^a   Beal, M Flint ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; [5,10,15,20 TETRAKIS(1,3 DIETHYLIMIDAZOLIUM 2 YL)PORPHYRINATO]MANGANESE PENTACHLORIDE; AEOL 10150; CELL PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; MALONALDEHYDE; MANGANESE DERIVATIVE; MANGANESE TETRAKIS(N,N' DIETHYLIMIDAZOLIUM 2 YL)PORPHYRIN; PORPHYRIN; ROFECOXIB; SMI 32 PROTEIN; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; DRUG STRUCTURE; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; MOLECULAR MODEL; MOTOR NEURON DISEASE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; STEREOLOGY; SURVIVAL; TRANSGENIC MOUSE;

AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL COUNT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; FREE RADICALS; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; METALLOPORPHYRINS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; NEUROFILAMENT PROTEINS; RANDOM ALLOCATION; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS;

EID: 23244439603     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20552     Document Type: Article

References (26)

1. Strong M, Rosenfield J. Amyotrophic Lateral Sclerosis: a review of current concepts. Amyotroph Later Scler Other Motor Neuron Discord 2003;4:136-143.
2. Jackson M, Llado J, Rothstein JD. Therapeutic developments in the treatment of amyotrophic lateral sclerosis. Expert Opin Investig Drugs 2002;11:1343-1364.
3. Chiu AY, Zhai P, Dal Canto MC, et al. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 1995;6: 349-362.
4. Brooks KJ, Hill MD, Hockings PD, Reid DG. MRI detects early hindlimb muscle atrophy in Gly93Ala superoxide dismutase-1 (G93A SOD1) transgenic mice, an animal model of familial amyotrophic lateral sclerosis. NMR Biomed 2004; 17:28-32.
5. Morrison KE. Therapies in amyotrophic lateral sclerosis-beyond riluzole. Curr Opin Pharmacol 2002;2:302-309.
6. Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol 2003;53: 423-426.
7. Patel M, Day BJ. Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 1999;20:359-364.
8. 2-Dismutation. Mn(III) ortho-methoxyethylpyridyl- and dt-ortho-methoxyethylimidazolylporphyrins. Dalton Trans 2004;11;1696-1702.
9. Sheng H, Spasojevic I, Warner DS, Batinic-Haberle I. Mouse spinal cord compression injury is ameliorated by intrathecal cationic manganese(III) porphyrin catalytic antioxidant therapy. Neurosci Lett 2004;366:220-225.
10. Crow JP. Peroxynitrite scavenging by metalloporphyrins and thiolates. Free Radic Biol Med 2000;28:1487-1494.
11. Wu AS, Kiaei M, Aguirre N, et al. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 2003;85:142-150.
12. Ferrer-Sueta G, Vitturi D, Batinic-Haberle I, et al. Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J Biol Chem 2003;278:27432-27438.
13. Kissner R, Beckman JS, Koppenol WH. Peroxynitrite studied by stopped-flow spectroscopy. Methods Enzymol 1999;301: 342-352.
14. Ferrante RJ, Shinobu LA, Schulz JB, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 1997; 42:326-334.
15. Cha CI, Chung YH, Shin CM, et al. Immunocytochemical study on the distribution of nitrotyrosine in the brain of the transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res 2000;853:156-161.
16. Stewart VC, Heales SJ. Nitric oxide-induced mitochondrial dysfunction: implications for neurodegeneration. Free Radic Biol Med 2003;34:287-303.
17. Catania MV, Aronica E, Yankaya B, Troost D. Increased expression of neuronal nitric oxide synthase spliced variants in reactive astrocytes of amyotrophic lateral sclerosis human spinal cord. J Neurosci 2001;21:RC148.
18. Almer G, Vukosavic S, Romero N, Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999;72: 2415-2425.
19. Weydt P, Hong SY, Kliot M, Moller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 2003;14:1051-1054.
20. Hsu S, Raine L, Fanger H. Use of avidin-biotin-peroxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
21. Mackensen GB, Patel M, Sheng H, et al. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. J Neurosci 2001;21:4582-4592.
22. Batinic-Haberle I, Benov L, Spasojevic I, Fridovich I. The ortho effect makes manganese(III) meso-tetrakis(N-methylpyridinium-2-yl)porphyrin a powerful and potentially useful superoxide dismutase mimic. J Biol Chem 1998;273: 24521-24528.
23. Przedborski S, Donaldson D, Jakowec M, et al. Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis. Ann Neurol 1996;39:158-165.
24. Crow JP. Manganese and iron porphyrins catalyze peroxynitrite decomposition and simultaneously increase nitration and oxidant yield: implications for their use as peroxynitrite scavengers in vivo. Arch Biochem Biophys 1999;371:41-52.
25. Klivenyi P, Kiaei M, Gardian G, et al. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004;88:576-582.
26. Jung C, Rong Y, Doctrow S, et al. Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci Lett 2001;304:157-160.